Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2013 May 1;12(7):1343–1355. doi: 10.1158/1535-7163.MCT-13-0100

Figure 2.

Figure 2

Cell survival curves of multidrug resistant (MDR) cells and the corresponding parental cells towards topotecan are shown in (A) HEK293 and transfected HEK293/ABCB1 cells (B) NSCLC-H460 and paclitaxel selected ABCB1 overexpressing H460/TX-50 cells (C) HEK293 and transfected HEK293/ABCG2-R2 cells (D) NSCLC-H460 and mitoxantrone-selected ABCG2 overexpressing H460/MX-20 cells (E) Parental (LLC/PK1-CMV) and ABCC2-transfected LLC/PK1-hMRP2 cells (F) Parental (NIH-3T3/pSRα) and ABCC4-transfected NIH-3T3/MRP4-3 cells. Cell survival was determined by MTT assay as described in the Materials and Methods. Data points represent the means ± SD of triplicate determinations performed at least three independent times. The resistance fold (RF) was calculated by dividing the IC50 (concentrations required to inhibit growth by 50%) for the MDR cells by that of the parental sensitive cells. The statistical differences were determined using the Student's t-test with significant differences based upon *, P < 0.05; **, P < 0.01; ***, P < 0.001 compared with parental cells.